Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

Main Article Content

Caroline Robert
Jean Grob
Daniil Stroyakovskiy
Boguslawa Karaszewska
Axel Hauschild
Evgeny Levchenko
Vanna Sileni
Jacob Schachter
Claus Garbe
Igor Bondarenko
Paul Nathan
Antoni Ribas
Michael Davies
Keith Flaherty
Paul Burgess
Monique Tan
Eduard Gasal
Dirk Schadendorf
Georgina Long

Keywords

Melanoma, BRAF, Patient Characteristics

Abstract

Abstract not available.

References

1. Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis PharmaceuticalsCorporation; 2020.

2. Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis PharmaceuticalsCorporation; 2020.

3. Tafinlar (dabrafenib) [summary of product characteristics]. Camberley, UK: NovartisPharmaceuticals UK Ltd; 2020. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Accessed July 31, 2020.

4. Mekinist (trametinib) [summary of product characteristics]. Camberley, UK: NovartisPharmaceuticals UK Ltd; 2020. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Accessed July 31, 2020.

5. Robert C, et al. N Engl J Med. 2019;381:626-636.

6. Nathan P, et al. J Clin Oncol. 2019;37:abstract 9507.

7. Long GV, et al. Lancet Oncol. 2016;17:1743-1754.

8. Osgood C, et al. J Clin Oncol. 2019;37:abstract 9508.

9. McCoach CE, et al. Ann Oncol. 2017;28:2707-2714.